Positron emission tomography (PET) is actively used in a diverse range of applications in
oncology, cardiology, and neurology. The use of PET in the clinical setting focuses on static …

The prevalence of Alzheimer's disease is projected to reach 13 million in the US by 2050.
Although major efforts have been made to avoid this outcome, so far there are no treatments …

Abstract Introduction The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD)
Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid …

Purpose We aimed to investigate associations between tau pathology and relative cerebral
blood flow (rCBF), and their relationship with cognition in Alzheimer's disease (AD), by using …

Background Detecting subtle-to-moderate biomarker changes such as those in amyloid PET
imaging becomes increasingly relevant in the context of primary and secondary prevention …

Alzheimer disease (AD) neuropathologic changes are β-amyloid (Aβ) deposition, pathologic
tau, and neurodegeneration. Dual-phase amyloid PET might be able to evaluate Aβ …

Abstract Purpose Early-onset Alzheimer's disease (EOAD) and late-onset Alzheimer's
disease (LOAD) differ in neuropathological burden and type of cognitive deficits. Assessing …

Alzheimer's disease (AD), a serious neurodegenerative disease, is pathologically
characterized by synaptic loss and dysfunction. Synaptic vesicle protein 2A (SV2A) is an …

Background Mixed results in the predictive ability of traditional biomarkers to determine
cognitive functioning and changes in older adults have led to misdiagnosis and …

Purpose Dynamic positron emission tomography (PET) protocols allow for accurate
quantification of [18 F] flortaucipir-specific binding. However, dynamic acquisitions can be …